BiomEdit's First-of-its-Kind Engineered Bacterial Biologic for Poultry Receives Conditional Licensure from USDA

Conditional licensure, achieved in just over four years, gives poultry producers an option to reduce the impact of necrotic enteritis; commercial evaluation programs begin at major U.S. poultry producers

INDIANAPOLIS, Sept. 29, 2026 /PRNewswire/ -- BiomEdit, a pioneering animal health biotechnology company, today announced that the U.S. Department of Agriculture's Center for Veterinary Biologics (USDA CVB) has granted conditional licensure for its lead candidate, Clostridium Perfringens Alpha Toxin and NetB Antibody Fragment, Live Limosilactobacillus Vector (CPerf LLV), previously referred to as BE-101, based on the demonstration of a reasonable expectation of efficacy in terms of reduced necrotic enteritis (NE)-associated mortality in broiler chickens challenged with Clostridium perfringens. 

USDA conditional licensure enables earlier market access for products that demonstrate safety and a reasonable expectation of efficacy, helping address animal diseases with limited treatment options while additional data are generated for full licensure. BiomEdit will continue advancing CPerf LLV toward full licensure.

The conditional licensure step marks a major regulatory and commercial milestone for BiomEdit, advancing CPerf LLV from development into initial market evaluation. BiomEdit believes CPerf LLV is the first genetically engineered probiotic biologic licensed for use in any animal species worldwide, establishing a precedent for a new class of Programmable Veterinary Biologics™.
 

CPerf LLV, expected to assume the brand name Optavant™ upon full licensure, is a first-of-its-kind programmable veterinary biologic engineered against Clostridium perfringens toxins, a primary driver of NE-related disease, mortality and productivity losses. This non-antibiotic approach is designed to give producers an option for NE beyond antibiotics, supporting an abundant food supply and animal welfare. A widely cited industry analysis estimates that NE costs the global broiler industry up to $6 billion annually in production losses and control measures.

"USDA conditional licensure of CPerf LLV is a defining moment for BiomEdit and for animal health," said Aaron Schacht, CEO of BiomEdit. "In just over four years since our founding, we have advanced from an ambitious scientific vision to a conditionally licensed product ready for the market. This milestone reflects the extraordinary talent of our team, the confidence of our investors, the commitment of our partners and USDA CVB's willingness to embrace innovation. More importantly, it validates our belief that programmable biologics can fundamentally expand what is possible in animal health."
 

"From our initial investment, we believed BiomEdit had the potential to create an entirely new category in animal health," said Brett Wong, Partner at Anterra Capital. "Achieving conditional licensure of CPerf LLV demonstrates the team's ability to translate breakthrough science into commercial products. We look forward to supporting BiomEdit as it continues to build one of the world's leading animal health biotechnology companies."

BiomEdit has initiated a commercial evaluation program with three major U.S. poultry producers, with CPerf LLV expected to be deployed in more than 35 million broilers. The program gives producers the opportunity to evaluate CPerf LLV in their production systems.

BiomEdit's pivotal efficacy study, reviewed by USDA CVB, demonstrated a 48.7% reduction in NE-associated mortality in broiler chickens, from 13.1% in challenged controls to 6.6% in birds receiving CPerf LLV.

Separately, results published in npj Biofilms and Microbiomes, a Nature portfolio journal, demonstrated that in a controlled study of subclinical NE, probiotic-delivered nanobodies targeting alpha toxin and NetB improved broiler weight gain and feed conversion, outperforming both prophylactic antibiotics and the parent probiotic strains. The published study data were not reviewed by USDA as part of the conditional licensure process.

"We have been encouraged by the level of interest from poultry producers as we move from regulatory approval into real-world use," said Andrew Carlson, Chief Commercial Officer at BiomEdit. "These evaluation trials give producers the opportunity to see how CPerf LLV performs in their systems, which is especially important for a novel biologic technology. Our goal is to provide a practical, scalable, non-antibiotic tool for a disease where solutions are needed."

The USDA conditional license is held by Diamond Animal Health, BiomEdit's contract development and manufacturing partner.

"Commercializing a first-of-its-kind biologic requires close collaboration and operational excellence," said Dean Warras, CEO of Diamond Animal Health. "We're proud to partner with BiomEdit as they bring this important innovation to poultry producers and help establish the future of advanced veterinary biologics."

The milestone comes as BiomEdit continues to expand its commercial portfolio and precision microbiome capabilities. In August, the company acquired Folium Science's technology platform and pipeline assets, including BiomElix® One, a poultry feed ingredient approved in Brazil, and the Guided Biotics® CRISPR-Cas technology. Together with CPerf LLV, these complementary technologies broaden BiomEdit's platform and expand its ability to design precise, differentiated solutions to improve animal health and productivity.

In parallel, BiomEdit has initiated its Series C financing round. Proceeds will fund CPerf LLV's commercial launch and path to full licensure, advance pipeline programs and expand and accelerate development of its Programmable Veterinary Biologics platform, including intellectual property and regulatory pathway development.

CPerf LLV label indication: This product has shown a reasonable expectation of efficacy for passive immunity of healthy chicks against Clostridium perfringens. Duration of passive immunity has not been determined. The license is conditional; efficacy and potency have not been fully demonstrated.

About BiomEdit

BiomEdit is pioneering Programmable Veterinary Biologics™, a new class of engineered microbial strains that target specific biological activity addressing key challenges in livestock and pets. The company is advancing programs in infectious disease, chronic disease and sustainability. Its lead product, Clostridium Perfringens Alpha Toxin and NetB Antibody Fragment, Live Limosilactobacillus Vector (CPerf LLV), previously referred to as BE-101, has received USDA conditional licensure based on the demonstration of a reasonable expectation of efficacy in terms of reduced NE-associated mortality in broiler chickens challenged with Clostridium perfringens. Founded in 2022, BiomEdit is backed by leading investors including Anterra Capital, Viking Global Investors, Nutreco, AgriZeroNZ, Elevate Ventures, Betagro Ventures and others. Biomedit.com 

Media Contact:

Julie Lawless
[email protected] 
+1 615-585-5861

SOURCE BiomEdit